Synthesis, spectroscopic characterisation and electron-transfer properties
FDA adverse event data (as of early 2025) 455+ adverse event reports linked to compounded semaglutide 320+ adverse event reports linked to compounded tirzepatide Many involved dosing errors from multidose vials, some requiring hospitalization Reports include severe nausea, vomiting, dehydration, and overdose symptoms Documented contamination, mislabeling, and counterfeit product cases 1
During childhood and adolescence, high GH is essential for growth
*Compounded versions of semaglutide are not FDA-approved, and neither the FDA nor any global regulatory agency has reviewed these products for safety, quality, or efficacy
GLP-1s are primarily used to treat diabetes and obesity by mimicking hormones to regulate blood sugar and reduce appetite